BioSpace News Archive

Eurofins Environment Testing Launches PFAS Exposure™ Self-Collection Blood Test

Eurofins Environment Testing Launches PFAS Exposure™ Self-Collection Blood Test.

December 1, 2021
·
2 min read
Drug Development

Accutar Biotechnology Announces First Patient Dosed with AC0682 in Phase 1 Study in Patients with ER-Positive / HER2-Negative Locally Advanced or Metastatic Breast Cancer

Accutar Biotechnology, Inc today announced the dose administration for the first patient in a Phase 1 study of AC0682, an orally bioavailable, chimeric degrader molecule designed to target and degrade ERα protein with high potency and selectivity.

December 1, 2021
·
2 min read
Pharm Country

Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.

Teva Pharmaceuticals today announced the launch of an authorized generic of Epiduo® 1 Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the United States.

December 1, 2021
·
7 min read
Business

Premas Biotech and Oravax Medical to Test Their Triple Antigen Oral Vaccine Candidate Against Omicron Variant of Concern

Premas Biotech announced today that its joint venture Oravax will initiate testing of their oral virus-like particle (VLP) vaccine candidate against Omicron variant of SARS-CoV 2 virus through preclinical, in vitro and challenge studies to assess its efficacy for the new mutant strain.

December 1, 2021
·
2 min read
Biotech Bay

Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting

Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET.

December 1, 2021
·
2 min read
Business

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total.

December 1, 2021
·
16 min read
Drug Development

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIGSurface to receive $30 million milestone payment upon first patient treated in the Phase 1 study

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for GSK4381562 (formerly SRF813) to proceed into a first-in-human clinical trial.

December 1, 2021
·
4 min read
BioMidwest

Genesis Innovation Group’s cultivate(MD) Capital Funds announces Virtual Incision’s Closing on $46 Million in Financing

Genesis Innovation Group’s cultivate(MD) Capital Funds announces that one of their portfolio companies, Virtual Incision Corporation, a medical device company pioneering first-of-its-kind miniaturized robots for laparoscopic surgery, has raised $46 million in a Series C funding round.

December 1, 2021
·
5 min read
Biotech Beach

Genomic Testing Cooperative to Present data at the American Society of Hematology Meeting on its Proprietary Machine Learning Approaches for RNA Transcriptome Data and on the Use of Liquid Biopsy

Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the annual American Society of Hematology (ASH) meeting.

December 1, 2021
·
5 min read
Business

AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer

AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer.

December 1, 2021
·
6 min read